Applying Recent Advances in Psoriasis to Clinical Practice: Piecing the Puzzle Together to Optimize the Patient Experience




Psoriasis is an immune-mediated chronic skin condition that also has effects on other systems of the body and is associated with several other debilitating conditions, such as diabetes, heart disease, and mental disorders. Psoriasis represents a huge healthcare burden, and afflicted patients report high economic costs and a poor quality of life. An improved understanding of the pathophysiology of the disease has led to the development and approval of several novel therapies, and the treatment landscape has been constantly evolving. Given that new evidence continues to be reported and that therapy recommendations keep changing, it is paramount that dermatologists and other healthcare clinicians are up-to-date on recent safety and efficacy outcomes and are able to provide individualized care for diverse patients with complex comorbid conditions. Current clinical practice, however, has been lagging behind, and many clinicians face challenges in effectively employing multidisciplinary and patient-centered approaches to improving patient outcomes.


April Armstrong, MD, MPH
Associate Professor of Clinical Dermatology
Associate Dean of Clinical Research
Keck School of Medicine
University of Southern California
Los Angeles, California


Release date: December 14, 2020
Expiration date: December 14, 2021
Estimated time to complete activity: 1.0 hour(s)



This educational initiative has been designed for dermatologists, nurse practitioners, and physician assistants involved in the management of patients with psoriasis.


Upon completion of this educational activity, participants should be able to:

  • Summarize the signs, symptoms, and pathophysiology of psoriasis
  • Evaluate the mechanism of action, safety, and efficacy of novel agents in targeting the underlying pathophysiology of psoriasis
  • Employ updated recommendations and guidelines to select systemic therapy for patients with psoriasis per the latest clinical evidence
  • Apply multidisciplinary and patient-focused strategies to improve outcomes and satisfaction among patients with psoriasis and other comorbidities

There are no fees for participating and receiving CME credit for this activity. During the period of December 14, 2020 through December 14, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.




Purdue College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Purdue College of Pharmacy designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about the accreditation of this activity, please contact Purdue College of Pharmacy at 


Purdue College of Pharmacy requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Purdue College of Pharmacy for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

April W. Armstrong, MD, MPH
Consulting Fees: AbbVie, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen Pharmaceuticals, Leo Pharma, Modernizing Medicine, Novartis, Ortho
Contracted Research: AbbVie, Bristol-Myers Squibb, Dermira, Eli Lilly, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Leo Pharma, Novartis, Regeneron Pharmaceuticals

Purdue College of Pharmacy and Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Purdue College of Pharmacy, Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


Co-provided by Purdue College of Pharmacy and Integrity Continuing Education, Inc.


Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Continue to Pretest